Hypopituitarism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Iqra Qamar (talk | contribs) |
m (Bot: Removing from Primary care) |
||
| Line 13: | Line 13: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| |||
{{WH}} | |||
{{WS}} | |||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 22:19, 29 July 2020
|
Hypopituitarism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypopituitarism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hypopituitarism secondary prevention |
|
Risk calculators and risk factors for Hypopituitarism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2] , Ahmed Elsaiey, MBBCH [3]
Overview
Secondary prevention may be done by long term monitoring of patients for complications of hormonal replacement therapy and by dose adjustments in stressful situations.
Secondary Prevention
- Secondary prevention may be done by long term monitoring of patients:
- For complications of hormonal replacement therapy (under-replacement/over replacement)[1]
- By adjusting the dosages in stressful situations
References
- ↑ Harsch IA, Schuller A, Hahn EG, Hensen J (2010). "Cortisone replacement therapy in endocrine disorders - quality of self-care". J Eval Clin Pract. 16 (3): 492–8. doi:10.1111/j.1365-2753.2009.01149.x. PMID 20210825.